PPARA and metabolic syndrome: Fenofibrate, the peroxisome proliferator-activated receptor alpha (PPARA) agonist used for dyslipidemia, stimulated mitochondrial FA beta-oxidation, restored left ventricular function, and reduced myocarditis and fibrosis in a murine model of chronic CCC [199].